Tin tức & Cập nhật

In patients with metabolic dysfunction-associated steatotic liver disease (MASLD), mid-term mortality increases in the presence of hepatic inflammation and fibrosis, as reported in a study.

Following an amylase trypsin inhibitors (ATI)-free diet for 6 weeks appears to produce substantial improvements in liver and metabolic, as well as patient-reported outcomes, in people with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a proof-of-concept study.

Third-line rescue therapy appears to be a promising therapeutic strategy in acute severe ulcerative colitis, with a recent study showing that such an approach helps avoid colectomy in most patients.

People with paediatric-onset immune-mediated inflammatory diseases (pIMID) have a roughly fourfold increased risk of death in adulthood, as suggested in a study.

Use of panobinostat in combination with vincristine and irinotecan chemotherapy provides effective tumour response in models developed from patients with high-risk, relapsed, and treatment-refractory hepatoblastoma (HB), according to a study.

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

Treatment with mycophenolate mofetil (MMF) in combination with prednisolone results in better biochemical remission rates at 24 weeks than the use of azathioprine plus prednisolone in patients with treatment-naïve autoimmune hepatitis (AIH), reports a study.

Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.